CompletedPhase 3NCT01694186
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
Studying Posterior uveitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EyePoint Pharmaceuticals, Inc.
- Principal Investigator
- Glenn Jaffe, MD, MDDuke University Eye Center
- Intervention
- FAI insert(drug)
- Enrollment
- 129 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2018
Study locations (30)
- Retina Vitreaous Associates, Beverly Hills, California, United States
- Retinal Consultants Medical Group, Inc, Sacramento, California, United States
- Retina Macula Institute, Torrance, California, United States
- Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
- Northwestern University, Chicago, Illinois, United States
- Ophthalmology & Visual Sciences, Lexington, Kentucky, United States
- Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Retina Consultants, Slingerlands, New York, United States
- Duke University Eye Center, Durham, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- OHSU Casey Eye Institute, Portland, Oregon, United States
- Charleston Neuroscience Institute, Ladson, South Carolina, United States
- Texas Retina Associates, Arlington, Texas, United States
- Retina Consultants of Houston, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01694186 on ClinicalTrials.gov